One Size Doesn't Fit All
A new study questions the effectiveness of breast cancer screening methods. For a long time, the standard advice has been that every woman should get a mammogram once a year.
(The American Cancer Society recommends annual screening specifically for women 45 to 54. (Women aged 40–44 have the choice to start yearly screening if they wish).
However, a major new study suggests that a "personalized" schedule—based on your specific health risks—works just as well as the standard yearly check-up.
Key Findings from the Study
Who led the study? Dr. Laura Esserman, from the University of California, San Francisco (UCSF), led the WISDOM study.
What did they do? Starting in 2016, researchers studied over 28,000 women aged 40 to 74. They compared two groups:
- Women who got the standard mammogram every single year.
- Women who were screened based on their personal risk level (genetic history, lifestyle, etc.).
What was the result? The study found that customizing the schedule was just as effective at detecting cancer as the rigid yearly schedule
- High Risk: Women with a higher chance of getting cancer might need screening more often.
- Low Risk: Women with a lower chance might be able to screen less often safely.
The Bottom Line: We may be moving toward a system in which your screening schedule is tailored to you, rather than following a single rule for everyone, without compromising safety.
How the Study Was Conducted
To ensure the results were fair, the researchers followed a strict process:
- Clean Slate: The study started with women who were healthy and had no history of breast cancer.
- The Split: Participants were randomly assigned to one of two groups (like flipping a coin):
- Group A: Followed a personalized schedule based on their specific risk.
- Group B: Followed the standard yearly schedule.
- The Timeline: Doctors monitored everyone’s health for an average of five years.
The Reassuring Result
The main worry with changing a schedule is usually, "What if we miss something?" This study suggests that it didn't happen.
Whether women were screened more frequently (because they were high risk) or less frequently (because they were low risk), the detection rate was the same as the group getting checked every year.
Key Takeaway: Personalized schedules successfully caught cancer just as well as the yearly routine. Moving to a customized schedule did not result in missed diagnoses.
The Shift to Precision Screening
"We treat breast cancer screening like a peanut butter spread—we spread it evenly across the population," Esserman explains. "But biology is not evenly distributed."
This realization is the cornerstone of the WISDOM study. Current guidelines generally recommend age-based screening (often starting at age 40 or 50) regardless of a woman's individual biological profile. This "one-size-fits-all" model usually leads to two distinct failures:
- 1 Over-diagnosis in low-risk populations: Women with very low risk often undergo unnecessary procedures, biopsies, and anxiety over false positives or slow-growing lesions (like low-risk DCIS) that might never have threatened their lives.
- 2 Under-diagnosis in high-risk populations: Women with aggressive biology or genetic predispositions may develop interval cancer tumors that arise rapidly between scheduled annual mammograms, because they are not being screened frequently enough or with the right tools (such as MRI).
To address this imbalance, the WISDOM study used a comprehensive risk assessment that went far beyond standard family history checks:
- Genetic Testing: Participants provided saliva samples to test for known high-risk mutations (like BRCA1 and BRCA2) as well as a "Polygenic Risk Score" (PRS), which analyzes hundreds of smaller genetic variations that, when combined, can significantly elevate risk.
- Breast Density: Higher breast density is both a risk factor for cancer and a factor that makes tumors more challenging to spot on traditional mammograms.
- Lifestyle and History: Factors such as hormone use, BMI, and personal medical history.
Based on this data, women were assigned a screening schedule tailored to them—ranging from annual (or even biannual) MRIs and mammograms for the highest-risk group to less frequent screening for those determined to be at the lowest risk.
A New Standard of Care?
The reduction in Stage 2B cancers suggests that by focusing resources on the women who need them most, the medical community can catch dangerous cancers earlier. "It’s about looking smarter, not just looking more," Esserman notes.
The results of WISDOM could pave the way for a significant update to national screening guidelines. Instead of a blanket recommendation based solely on age, the future of breast cancer prevention may involve a "risk assessment" appointment at age 40 (or earlier), where a woman's genetic and biological profile determines her lifelong screening roadmap.
Addressing the Equity Gap
A critical component of the WISDOM study was ensuring that these "smarter" screening tools work for everyone, not just women of European descent. Historically, polygenic risk scores—the genetic calculations used to estimate cancer risk—were developed using databases primarily composed of white women. This created a significant blind spot in precision medicine, potentially rendering risk assessments less accurate for African American, Hispanic, and Asian women.
To counter this, Esserman and her team prioritized diversity in recruitment. By validating the risk algorithms across different demographic groups, the study aims to close the racial disparity gap in breast cancer mortality—particularly for Black women, who are 40% more likely to die from the disease than white women despite having similar incidence rates. "If we are going to change the standard of care, it has to be a standard that applies to all women," Esserman emphasizes. "Precision medicine cannot be a privilege; it must be a tool for equity."
From Detection to Prevention
Perhaps the most transformative potential of the risk-based approach lies in shifting the focus from simply finding cancer to preventing it.
For women identified as high-risk, the protocol offers more than just frequent MRIs; it opens the door to proactive interventions. This includes discussions about "chemoprevention"—using drugs like tamoxifen or raloxifene to block estrogen receptors and lower the chances of cancer developing—as well as targeted lifestyle modifications.
Conversely, for the large percentage of women found to be at low risk, the benefit is psychological as well as physical. Reducing the frequency of mammograms spares them from "scanxiety," false alarms, and unnecessary biopsies that often result from over-screening.
The Path Forward
While the data is promising, implementing a personalized screening model on a national scale faces logistical hurdles. It requires a shift in infrastructure: insurance companies must update coverage policies to pay for genetic testing and risk assessments at age 40, and primary care providers need training to interpret these risk profiles.
However, the momentum is undeniable. With the WISDOM study demonstrating that a personalized schedule is just as safe as the annual standard, while significantly reducing false positives and focusing resources where they are needed most, the era of the "one-size-fits-all" mammogram may be drawing to a close. As the medical community digests these findings, the message to women is becoming clear: knowing your individual biology is the most powerful tool you have!
